Products
NanoFect Transfection Reagent
Unique blend of polymers to deliver more DNA and siRNAs to cells
Catalog Number
NF100
Unit
1 mL
Shipping Condition
Room Temperature - 2 Day Shipping
Volume
1 mL
Have questions? Contact us
Highlights
- Efficient gene delivery for most cell types
- Nanotechnology-based reagent with low toxicity
- Cost-effective alternative to lipid-based products
- Simple protocol for high-throughput transfection
Description
Specifications
Documents
Protocol
Publications
NanoFect™ transfection reagent is a nanotechnology-based reagent with low toxicity providing efficient gene delivery for most cell types.
| Product Name | NanoFect Transfection Reagent |
|---|---|
| Shipping Condition |
Room Temperature - 2 Day Shipping |
| Storage and Stability |
4°C, 6 months |
| Quality Control | Each lot of NanoFect™ Transfection Reagent is functionally tested in transfection assays with human embryonic kidney 293 cells. |
| Restricted Use |
For Research Use Only. Not for use in diagnostic or therapeutic procedures. |
- L Zhang, X Zhou, S Aryal, V Veasey, P Zhang… CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator. Cell Death & …, 2024. Article
- NH Elder, A Majd, EA Bulger, RM Samuel… Distinct differentiation trajectories leave lasting impacts on gene regulation and function of V2a interneurons. bioRxiv, 2024. Article
- YA Lu, J Sun, L Wang, M Wang, Y Wu… ELM2‐SANT Domain‐Containing Scaffolding Protein 1 Regulates Differentiation and Maturation of Cardiomyocytes Derived From Human‐Induced Pluripotent Stem …. Journal of the …, 2024. Article
- M Khoroshkin, A Buyan, M Dodel, A Navickas… Systematic identification of post-transcriptional regulatory modules. Nature …, 2024. Article
- M Khoroshkin and A Buyan and M Dodel and A Navickas and J Yu and ... Systematic Identification of Post-Transcriptional Regulatory Modules. bioRxiv, 2023. Article
- AS Verkman and O Cil and PM Haggie SLC26A3 inhibitors and use thereof. US Patent 11,591,304, 2023. Article
- I Jancewicz and M Śmiech and M Winiarska and ... New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer Immunology …, 2024. Article
- L Wu and V Golubovskaya HUMANIZED CD37 AND Bl-SPECIFIC CD19-HUMANIZED CD37 CAR-T CELLS. US Patent App. 18/006,651, 2023. Article
- MJ Powell Specific synthetic chimeric xenonucleic acid guide RNA; s (XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency. US Patent 11,845,934, 2023. Article
- MJ Powell SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s (XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY. US Patent App. 18/490,888, 2024. Article
- YZ Xu, Z Ding, ZY Fang, H Li, XP Jiang, YL Xie… An ultraconserved pseudo 5'splice site fine-tunes development by regulating alternative splicing within TOR-related pathways. , 2025. Article
- I Jancewicz, M Śmiech, M Winiarska… New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer Immunology …, 2024. Article
Have Questions?
If you don't see the product you're looking for, please don't hesitate to CONTACT US. Our dedicated team of scientists will provide you our best solutions for your desired results.